USC prof to oversee HIFU trial
Inderbir S. Gill, MD, professor and chairman of the department of urology at the Keck School of Medicine of the University of Southern California and founding director of the USC Institute of Urology, has been selected to oversee an FDA clinical trial of EDAP's high-intensity focused ultrasound (HIFU) system at various investigational sites in the U.S.
HIFU has been shown to be a minimally invasive and effective option with a low occurrence of side effects for the treatment of localized prostate cancer, according to EDAP. Gill will supervise a team of investigators in evaluating the results of HIFU within selected patients presenting low-risk, organ-confined prostate cancer.
Gill, who began consulting with France–based EDAP in March 2009, was elected to the American Association of Genito-Urinary Surgeons in 2003 and was also awarded the St. Paul's Medal by the British Urological Association (BAUS).
HIFU has been shown to be a minimally invasive and effective option with a low occurrence of side effects for the treatment of localized prostate cancer, according to EDAP. Gill will supervise a team of investigators in evaluating the results of HIFU within selected patients presenting low-risk, organ-confined prostate cancer.
Gill, who began consulting with France–based EDAP in March 2009, was elected to the American Association of Genito-Urinary Surgeons in 2003 and was also awarded the St. Paul's Medal by the British Urological Association (BAUS).